Research
Hormonal
Tirzepatide demonstrates unprecedented efficacy for glycaemic control, reductions in body weight, and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists.
Tirzepatide may be a highly effective treatment option for managing glycaemic control and weight in patients with T2D and obesity.
StrongSupportsmedium confidence
Tirzepatide...with unprecedented efficacy for glycaemic control, reductions in body weight and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists.
Why this rating
The claims are based on clinical trials, which are high-quality evidence.
Source
Cardiovascular effects of tirzepatide
Priya Sumithran et al. · Journal of Endocrinology · 2025
DOI 10.1530/joe-24-0259
otherCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →